CAC
BBOT

Cowen and Company’s BridgeBio Oncology BBOT Stock Holding History

Cowen and Company’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,048
Closed -$471K – 325
2024
Q3 		$471K Sell
45,048
-5,463
-11% -$56.5K 0.02% 182
2024
Q2 		$516K Sell
50,511
-3,902
-7% -$40.2K 0.01% 176
2024
Q1 		$566K Buy
+54,413
New +$563K 0.02% 185

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Cowen and Company's BBOT Position: Q4 2024 in Review

Cowen and Company sold out of BridgeBio Oncology (BBOT) in Q4 2024, closing a stake of 45,048 shares — an estimated $471K sold.

Cowen and Company first reported a position in BBOT in Q1 2024 and held it in 3 quarters. The position peaked at $566K in Q1 2024. 32 funds tracked by Wall St. Rank hold BBOT as of Q4 2024.

  • Cowen and Company reported no remaining BridgeBio Oncology position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 45,048 BridgeBio Oncology shares in Q4 2024, an estimated $471K.
  • Cowen and Company first reported a position in BridgeBio Oncology in Q1 2024 and held it in 3 quarters.
  • Cowen and Company's BridgeBio Oncology position peaked at $566K in Q1 2024.
  • 32 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.